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Abstract: Vitamin D deficiency is highly prevalent among children and adults worldwide. Agreement
exists that vitamin D deficiency should be corrected. However, the definitions of vitamin deficiency
and effective vitamin D replacement therapy are inconsistent in the literature. Not only is the
dosing regimen still under debate, but also the time and period of administration (i.e., daily vs.
monthly dose). In pediatric as well as elderly subjects, dosing regimens with high vitamin D doses
at less frequent intervals were proposed to help increase compliance to treatment: these became
widespread in clinical practice, despite mounting evidence that such therapies are not only ineffective
but potentially harmful, particularly in elderly subjects. Moreover, in the elderly, high doses of
vitamin D seem to increase the risk of functional decline and are associated with a higher risk of falls
and fractures. Achieving good adherence to recommended prophylactic regimens is definitely one
of the obstacles currently being faced in view of the wide segment of the population liable to the
treatment and the very long duration of prophylaxis. The daily intake for extended periods is in fact
one of the frequent causes of therapeutic drop-outs, while monthly doses of vitamin D may effectively
and safely improve patient compliance to the therapy. The aim of our paper is a quasi-literature
review on dosing regimens among children and elderly. These two populations showed a particularly
significant beneficial effect on bone metabolism, and there could be different outcomes with different
dosing regimens.
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1. Introduction
The importance of vitamin D in bone metabolism is very well-known. Vitamin D deficiency is
associated with increased risk for other non-musculoskeletal chronic diseases [1].
Vitamin D deficiency and insufficiency are highly prevalent among children worldwide [2]. In the
adult population, the prevalence of vitamin D deficiency is also high and ranges from 79% to 98% in
nursing home patients, increasing the risk of falls and fracture [3,4].
There is still an ongoing discussion to define the optimal 25OH vitamin D (25OHD) serum level
for maintenance of bone health, and also what effective vitamin D replacement therapy should involve.
In other words, it is not clear which dosing regimens should be used in different populations. However,
the evolving consensus is now to recommend a 25OHD target level of 75 nmol/L in fragile elderly
subjects who are at elevated risk of falls and fractures, and at least a level of 50 nmol/L for the adult
population [3,4].
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Thus far, there is no general agreement regarding the dose or the D2/D3 of vitamin D
supplementation to reach the target level, even though there are several data showing the different
impacts on increasing circulating 25OHD levels in patients on vitamin D supplements, of characteristics
such as body mass index (BMI) (accounting up to 30% of variation in circulating 25OHD), type of
supplement (vitamin D2 or D3), age, concomitant intake of calcium supplements and baseline 25OHD [5].
The main point is related to the fact that, in clinical practice, maintaining long-term adherence
to daily dosages of vitamin D is often difficult, in both pediatric and elderly populations [6]. As a
result, more convenient dosing regimens with high vitamin D doses at less frequent intervals were
proposed and became widespread practice, despite mounting evidence that such therapies are not
only ineffective but potentially harmful, particularly in adults [7].
While it has been shown an association between low 25OH vitamin D levels in childhood and
increased occurrence of subclinical atherosclerosis in adulthood [2], definitive data are lacking on
the effectiveness of vitamin D supplementation and dose requirements related to the improvement
of lower extremity function in elderly. Interestingly, several studies suggested that higher monthly
doses of vitamin D increase the risk of functional decline [8,9]. Until now, there are no consistent
data suggesting the ideal regimen of supplementation, or comparing daily vs. monthly vitamin
D administration.
In light of all the above questions, the aim of our paper is to evaluate dosing regimens among
different populations, with particular attention to children and the elderly, to identify the best way to
correct vitamin D deficiency, and to define the optimal 25OH vitamin serum level.
2. Vitamin D in the Childhood
2.1. The First Year of Life
In the first year of life, vitamin D status depends mainly on prophylaxis protocol. Breast milk
contains insufficient amounts of vitamin (<80 IU/L) for vitamin D deficiency prevention [10]. Subjects
under the age of six months should not be exposed to direct sunlight and in the winter period babies
who are exclusively breastfed have lower blood levels of 25(OH)D. To prevent vitamin D deficiency, the
American Academy of Pediatrics has recommended a supplement of 400 IU/day from birth for children
entirely or partially breastfed [11]. This supplementation is recommended until the child is weaned
and drinks at least one liter/day of formula milk fortified with vitamin D. In Italy, Reference Levels
of Nutrients and energy intake (LARN) recommend an intake of 400 IU/day between six and twelve
months of life [12]. The Italian Society of Paediatrics similarly recommends prophylaxis with 400 IU/day
of vitamin D for all infants from the first day of life up to one year of age, regardless of the type of feeding.
This dosage is recommended for infants in the absence of risk factors for vitamin D deficiency [13]. Table 1
reports the international recommendations of vitamin D in subjects from birth to one year of age.
Table 1. Recommendations for vitamin D prophylaxis in the first year of life according to several
international health Societies.
Society Vitamin D Supplementation
Society of Lawson Wilkins Pediatric
Endocrinology (Misra 2008 [14])
- 400 IU/day should be initiated from the first day of life in all breastfed babies, and
children not breastfed do not take at least one liter/day of milk formula fortified with
vitamin D.
- Children with dark skin or who live at high latitudes (>40◦) may require vitamin D
supplementation at higher doses (800 IU/day), especially during the winter months.
ESPGHAN (Braegger 2013 [15]) 400 IU/day of vitamin D in all children during the first year of life.
AAP (Wagner 2008 [11], Golden 2014 [16])
Children breastfed or partially breastfed with 400 IU/day from the first day of life.
Supplementation until the child is weaned and takes at least 1 liter/day of vitamin
D-fortified milk formula.
Endocrine Society (Holick 2011 [17]) Children in the first year of life at risk of vitamin D deficiency should receivesupplementation with 400 IU/day to 1000 IU/day.
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Table 1. Cont.
Society Vitamin D Supplementation
Health Canada and the Canadian
Paediatric Society [18]
0–6 months
- 400 IU/day in breastfed children.
- Children who are not breastfed require prophylaxis with vitamin D because infant
formula contains vitamin D.
- Children partially breastfed 400 IU/day, regardless of how much formula milk taken.
6–12 months
- 400 IU/day in children who are still exclusively breastfed or who take breast milk.
United Kingdom Department of Health [19]
- All children between 6 months and 5 years: to ensure a 280 IU/day–340 IU/day
intake. Infants fed with formula milk do not require prophylaxis if they take at least
500 mL/day of formulation enriched milk with vitamin D.
- Breastfed babies may need to receive prophylaxis from the first month of life if the
mother did not take supplements during pregnancy.
Paediatric and Adolescent Bone Group UK
(Arundel 2012 [18])
It recommends that children fed exclusively by breastfeeding start prophylaxis
immediately after birth.
A French company of Paediatrics
(Vidailhet 2012 [19])
- Children fed exclusively by breastfeeding: 1000 IU/day–1200 IU/day for the entire
lactation.
- Children under 18 months of age who take milk fortified with vitamin D3: 600
IU/day–800 IU/day.
- Children under 18 months of age receiving unfortified cow’s milk with vitamin D3:
1000 IU/day–1200 IU/day.
A Spanish company of Paediatrics
(Martinez Suarez 2012 [20])
For the child in the first year of life: 400 IU/day or the use of formula milk sufficiently
enriched with vitamin D are the best strategies to ensure adequate vitamin intake.
Central Europe (Płudowski 2013 [21])
- Prophylactic vitamin D should start from the earliest days of life, regardless of the
type of feeding.
- 400 IU/day up to 6 months of life.
- 400 IU/day–600 IU/day between 6 and 12 months of life, according to the
contribution of vitamin D daily with the diet.
Australia and New Zealand
(Paxton 2013 [22]) Children at risk of vitamin D deficiency: 400 IU/day at least for the first year of life.
Daily vs. Monthly Dose
Most clinical studies suggested daily regimens of vitamin D administration. However, daily intake
of vitamin D must be supported by sufficient compliance from the family and subjects. Two recent
studies instead evaluated the use of prophylaxis with vitamin D in intermittent doses [23,24]. In the
first study, 120 children recruited during the vaccination campaign were divided into three groups:
200 IU/day, 400 IU/day, and 50,000 IU every two months. Subjects with 50,000 IU supplementation
every two months showed an increase of 25(OH)D higher than the other two groups. At 6 months, 97%
of the group of children treated with 50,000 IU every two months reached vitamin D levels ≥ 30 ng/mL
(vitamin D sufficient). Only 37% of children in the first group and 77% of children in the second group
reached the same level at follow-up. There were no reported cases of hypercalcemia or any other side
effects during the study [23]. The second study evaluated 82 breastfed babies born to mothers with
vitamin D deficiency. Children were divided into two groups. The first group (children with vitamin
D < 20 ng/mL) received 30,000 IU of vitamin D in a single dose in the first week of life, followed
by a second dose of 30,000 IU after a month if values of vitamin D were < 20 ng/mL. If at control
the values of 25(OH)D levels were > 20 ng/mL, the prophylaxis continued with daily administration
of 400 IU/day. The second group was supplemented with 400 IU/day from the second week of
life. At follow-up performed after two months, 100% of children supplemented with 30,000 IU in
a single dose showed levels of 25(OH)D > 20 ng/mL, with 93.3% having levels > 30 ng/mL. In the
second group, 65% had at follow-up levels of 25(OH)D > 20 ng/mL and 27.9% levels > 30 ng/mL.
The sufficient level of vitamin D (>30 ng/mL) was achieved in all cases only in children treated with
the first prophylactic scheme, while only 50% of children treated with 400 IU/day reached this blood
level of vitamin D. Both studied groups reported no side effects due to the administration of vitamin
D [24]. Single dose or monthly administered vitamin D would offer greater adherence to prophylaxis
by families and children and better efficacy in maintaining or increasing blood levels of vitamin D,
in the absence of side effects or toxicity [13].
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2.2. Children Aged 1–18 Years
Many international studies show that deficit and insufficiency of vitamin D, defined as blood
levels of 25(OH)D < 20 ng/mL or between 20 ng/mL and 29 ng/mL, are very common in
industrialized countries and in developing countries. A multicenter study conducted in Europe
on 1006 children between 12.5 years and 17.5 years found 42% of subjects with deficit and 39%
with vitamin D insufficiency [25]. Data collected from Italian children are similar to those from
Europeans and Americans, in particular the highest percentages of hypovitaminosis D are found
in the neonatal period [26] and adolescence [27–29]. Status of vitamin D in infants is influenced by
season of birth, ethnicity and maternal prophylaxis during pregnancy, while for adolescents and
children important factors include the season in which they get the dosage, sun exposure, ethnicity,
and BMI [13]. Important factors in children over one year of age are therefore sun exposure and
the presence of certain risk factors for vitamin D deficiency such as non-Caucasian ethnicity, renal
or liver failure, intestinal malabsorption, chronic treatment with anticonvulsants, corticosteroids,
ketoconazole, antiviral and obesity. The level of recommended daily intake of vitamin D according
to the American Academy of Pediatric and Italian LARN for Children between 1 and 18 years is
600 IU/day [30]. The Endocrine Society recommends for children at risk of deficiency an intake
of 600 IU/day–1000 IU/day. It is also recommended that obese people receiving anticonvulsants,
antiretrovirals, ketoconazole or corticosteroidsare recommended to receive an intake 2–3 times the daily
requirements of vitamin D by age [17]. The Society for Adolescent Health and Medicine recommends
supplementation with 600 IU/day in adolescents with no risk factors and of at least 1000 IU/day
in adolescents at risk for vitamin D deficiency or insufficiency, in addition to vitamin D assumed
with diet or produced during sun exposure [31]. These recommendations are important in order to
ensure a correct acquisition of bone mass which is known to have its peak in adolescence, a process in
which vitamin D is closely involved. Different international health organizations recommend doses of
vitamin D on a daily basis, with one or two additional administrations during the winter, with doses of
80,000 to 200,000 IU. The French Society of Paediatrics suggests that children from 18 months to 5 years,
with no risk factors for vitamin D deficiency should receive this dosage plus two supplementations
of 80,000 IU–100,000 during the winter. The same approach is proposed for adolescents: two similar
supplementary doses or a single dose of 200,000 IU during winter [19]. Mallet et al. recommend
extending the recommendations for adolescents to children between 6 and 10 years old [32]. Table 2
reports the international recommendations of vitamin D in subjects from 1 year to 18 years of age.
Table 2. Indications for vitamin D prophylaxis between 1 year and 18 years of life according to several
international health organizations.
Society Vitamin D Supplementation
The American Academy of Pediatrics
(Wagner 2008 [11], Golden 2014 [16])
Wagner 2008:
- Teenagers who do not get 400 IU/day of vitamin D through milk or other
fortified foods: 400 IU/day.
- Children with increased risk of vitamin D, malabsorption, anticonvulsants
treatment: 400 IU/day.
Golden 2014:
Children over one year of age and adolescents: 600 IU/day, obese subjects treated
with anticonvulsant drugs, corticosteroids, antifungal or antiretroviral drugs may
require 2–4 times the recommended dose of vitamin D.
Endocrine Society (Holick 2011 [17])
600 to 1000 IU/day.
Obese subjects treated with anticonvulsant drugs, corticosteroids, antifungals
such as ketoconazole and antiretroviral drugs should receive at least 2–3 times
the daily requirements of vitamin D for their age.
ESPGHAN (Braegger 2013 [15]) - UL: 2000 IU/day between 1 year and 10 years old, 4000 IU/day between11 years and 17 years.
Society for Adolescent Health and
Medicine (2013) [32]
600 IU/day (400 IU/day–800 IU/day according to the preparations available on
the market) in healthy adolescents, and supplementation with minimum
1000 IU/day in adolescents at risk of vitamin D deficiency.
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Table 2. Cont.
Society Vitamin D Supplementation
United Kingdom Department of Health [19]
All children between 6 months and 5 years: 280 IU/day–340 IU/day.
No supplement in children receiving at least 500 mL/day of formula milk
enriched with vitamin D.
French company of Pediatrics (Vidailhet 2012 [19])
- In children 18 months–5 years: 2 doses of 80,000 IU or 100,000 IU in winter
(November to February)
- 6 years to 18 years: 2 doses of 80,000 IU or 100,000 IU in the winter
(November to February) or a single dose of 200,000 IU.
A Spanish company of Pediatrics
(Martinez Suarez 2012 [20]) Daily intake: 600 IU/day
Central Europe (Płudowski 2013 [21])
- Supplementation with 600 IU/day to 1000 IU/day (depending on body weight)
of vitamin D and recommended between September and April.
- Supplementation with 600 IU/day to 1000 IU/day (depending on body weight)
of vitamin D and recommended throughout the year if good cutaneous
production of vitamin D is not guaranteed during the summer.
- In obese children and adolescents (BMI > 90th percentile for age and sex)
supplementation with 1200 IU/day–2000 IU/day (depending on the severity of
obesity) of vitamin D between September and April is recommended.
- In obese children and adolescents (BMI > 90th percentile for age and sex)
supplementation with 1200 IU/day–2000 IU/day (depending on the severity of
obesity) of vitamin D throughout the year is recommended.
- UL: 2000 IU/day between 1 year and 10 years old, 4000 IU/day between
11 years and 18 years.
Australia and New Zealand (Paxton 2013 [22]) In subjects 1 year–18 years old with risk factors for vitamin D deficiency:400U/day or 150,000 IU early autumn.
Daily vs. Monthly Dose
Some studies that evaluate schedules of vitamin D administration other than daily
supplementation offer encouraging results. Carnes et al. evaluated the efficacy and safety of high doses
given at intervals every six months for a year. The children were divided into three groups treated
with placebo, 150,000 IU every six months or 300,000 IU every six months. The study shows that the
best scheme is administration of 300,000 IU/6 months, as this has the highest percentage of patients
with normal vitamin D levels. During the study, there were no side effects and compliance remained
high [33]. Kuchay et al. showed that intermittent treatment with vitamin D is safe and effective at
achieving and maintaining adequate vitamin D levels. The administered dose was 60,000 IU/month
for a year. After a year of monthly supplementation, average levels of 25(OH)D had risen from
12.0 ng/mL at the start to 32.6 ng/mL at the end of the study, subjects with insufficiency were
reduced from 92.2% at time zero to 2.6% after 12 months, and none of the subjects developed cases
of hypercalcemia [34]. In the study of Ghazi et al., 210 children were divided into three groups: one
treated with 50,000 IU of vitamin D each month, the second with 50,000 IU every two months and the
third with placebo. Treatment with 50,000 IU/month proved effective in increasing vitamin D levels
but it does not seem to be enough to correct the deficit, in particular in young girls, who started the
treatment with vitamin D levels significantly lower than their male counterparts. (19.25 ± 16.00 vs.
14.00 ± 40.50 nmol/L) [35].
According to the Italian consensus on vitamin D in infants and children [13], vitamin D may
be given with intermittent schedule (weekly or monthly for a total dose 18,000 to 30,000 IU/month)
from the 5th or 6th year of life to adolescence in those subjects less compliant to daily treatment.
Although vitamin D deficiency is detrimental to bone health, the consequent idea that higher doses
are protective and confer a reduced risk of disease has been challenged by recent data in adults
that indicate that doses of high vitamin D raise the incidence of falls and fractures [36,37]. These
events were linked to the mode of administration (i.e., a single large bolus compared to smaller
intermittent doses) [38]. Beyond skeletal health, similar curvilinear or U-shaped response has been
described for other vitamin D outcomes, including all-cause mortality, cardiovascular disease and
selected cancers. For these reasons the Institute of Medicine suggests caution against maintaining
serum 25OHD concentrations above 50 ng/mL (125 nmol/L) [39], whereas levels up to 100 ng/mL
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(250 nmol/L) are cited as safe for both children and adults [17]. The specific vitamin D intake that
results in excess or intoxication and the severity of the corresponding hypercalcemia have not been
clearly established in pediatric age. Reports on vitamin D intoxication in infants and young children
typically describe cases of receiving extremely large doses, in the range of 2.4 million to 4.5 million
IU, or approximately 40,000 IU/kg to 560,000 IU/kg. This intake results in serum 25OHD levels in the
range of 250 ng/mL–670 ng/mL leading to severe hypercalcemia [40,41]. Serum calcium concentrations
in the range of 14–18 mg/dL (normal value: >3.5 mmol/L–4.5 mmol/L) were reported, with occasional
values as high as 20 mg/dL. Among these cases, there is significant variability in the amount of vitamin
D administered and the resulting serum 25OHD concentrations. Furthermore, even with comparable
serum 25OHD levels, the severity of hypercalcemia and symptomatology is unpredictable. Vogiatzi
et al. suggest some recommendations for the prevention of vitamin D excess and intoxication in
pediatrics [42]. They discourage empirical therapy of vitamin D deficiency with high vitamin D doses
(such as single high-dose oral Vitamin D (stoss) therapy) without previous documentation of 25OHD
concentrations and monitoring 25OHD and serum calcium levels. Health care providers should also
consider monitoring vitamin D levels in infants and children receiving treatment doses at the upper
ranges currently recommended. Although there is insufficient evidence to guide the frequency of such
testing, Vogiatzi et al suggest 25(OH)D measurements no more than every six months [42]. According
to these data, prophylaxis with vitamin D is critical to prevent hypovitaminosis D and the effects
on bone metabolism and the whole body. Attention should always be paid to the cumulative dose
administered and the risk of toxicity.
3. Vitamin D in the Elderly
3.1. Elderly Population
Patients over 70 years old represent a frail population in which vitamin D deficiency is
frequent and often associated with comorbidities, therefore recommendations for prevention and
supplementation of 25OHD are needed to maintain optimal vitamin D levels.
In of our study, we collected the main articles and guidelines published from 2011 to 2016
evaluating efficacy and safety of different vitamin D dosing regimens of supplementations in the elderly
population. There is no common agreement worldwide to define a standard dose of cholecalciferol to
prevent hypovitaminosis D. Current guidelines from the Institute of Medicine recommends a daily
intake of 800 UI, whereas the Endocrine Society Clinical Practice Guideline endorses an intake of
1500 UI–2000 UI daily in people aged 70 years and older [7,43].
Osteoporosis Australia recommends an intake of at least 800 IU in people over 70 years, and even
higher doses in specific conditions, such as sun avoiders [44].
In the United Kingdom, instead, people aged 65 years and over as well people with limited
sunlight exposure are advised to take daily vitamin D supplements of only 400 IU [45].
A “tailored” dose is likely to be more effective in maintaining vitamin D levels over the therapeutic
threshold, because of the high individual variability.
In Italy, the recommendations from the Italian Society for Osteoporosis, Mineral Metabolism
and Skeletal Diseases (SIOMMMS) to correct vitamin D deficiency are based on 25OHD baseline
levels and require a loading dose to be administered within few weeks plus a maintaining daily
supplement dose, similar to the dose regimen suggested by the UK National Osteoporosis Society
Practical Guides [45,46].
We did not find relevant results regarding the compliance to the therapy (no studies evaluated
the compliance as the primary endopoint), however poor adherence to daily dosing of medications
and supplements is reported. In the study by Binkley et al., from 2011, which followed 64 adults
over one year, the compliance to daily supplementation was slightly worse compared to monthly
supplementation (91–95% vs. 100%) [1].
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Another study, by Papaioannou et al., in 2011, showed the adherence to daily vitamin D
supplementation of 83% (patients who consumed at least 80% of tablets) [47]. Compliance in real
life is expected to be even lower than what is described in literature; a deferred administration of
supplements is supposed to be useful to obtain a higher adherence to the therapy and better 25-OHD
blood levels.
In the last few years, several trials comparing different daily or monthly dosing regimens of
vitamin D currently adopted worldwide resulted in 20–25% of patients having suboptimal vitamin D
status (at least 30 ng/mL), even when 50,000 IU were administered monthly (1600 IU/day) [1,47,48].
In addition, the relevant impact on circulating vitamin D levels of variables such as BMI, age or type
of supplements will probably lead to a personalized supplementation strategy tailored to the patient.
Table 3 reports the international recommendations of vitamin D supplements in the adult population.
Table 3. Indications for vitamin D supplements in the adult population according to the international
health organizations.
Society Vitamin D Supplementation
Institute of Medicine (2010 [43]) 600 IU/day, 18 years–70 years old800 IU/day, over 70 years old
Endocrine Society Clinical Practice Guideline (2011 [49]) 1500 IU/day–2000 IU/day, over 19 years old
Osteoporosis Australia (2016 [44])
At least 600 IU/day, under 70 years old
At least 800 IU/day, over 70 years old
Sun avoiders or people at risk of vitamin D deficiency:
1000 IU/day–2000 IU/day
National Osteoporosis Society Practical Guides (2013 [45]) People aged 65 years and over, people who are not exposed tomuch sun, pregnant and breastfeeding women: 400 IU/day
Italian guidelines for diagnosis, prevention and treatment
of osteoporosis (2015 [46])
Baseline vit. D level < 25 nmol/L: cumulative dose 600,000 IU
supporting dose 2000 IU/day
Baseline vit. D level 25 nmol/L–50 nmol/L: cumulative dose
400,000 IU supporting dose 1000 IU/day
Baseline vit. D level 50 nmol/L–75 nmol/L: cumulative dose
100,000 IU supporting dose 800 IU/day
Generally, these guidelines are based on 25OHD levels, and do not consider the impact of body
weight on increasing circulating 25OHD levels, which accounts for more than 30% of individual
variation [5].
3.1.1. Vitamin D, Weight and BMI
The influence of weight as well as BMI in conditioning the serum levels of vitamin D has already
been evaluated.
Zittermann et al. analyzed the potential determinants of vitamin D levels and found that dose per
kg body weight per day could explain 34.5% of variation in circulating 25OHD [5]. Additional significant
predictors were type of supplement (vitamin D2 or vitamin D3), age, concomitant intake of calcium
supplements and baseline 25OHD levels. Table 4 shows Vitamin D daily supplementation according to
weight, age and target 25OHD level 75 nmol/L, considering a baseline 25OHD level 25 nmol/L.
Table 4. Body weight impact on determining optimal vitamin D daily dose [5].
Body Weight (kg) 30-Year-Old Person 70-Year-Old Person
50 42 µg (1680 IU) 24 µg (960 IU)
75 63 µg (2520 IU) 36.5 µg (1460 IU)
100 84 µg (3360 IU) 49 µg (1960 IU)
Calculated daily vitamin D3 dose for achieving a target 25OHD of 75 nmol/L in vitamin D deficient
individuals, based on the paper by Zittermann et al. [5].
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Wijnen et al. underlined that the most effective way to correct vitamin D deficiency in elderly
subjects is to administer a personalized loading dose based on body weight and baseline 25OHD levels
within few weeks to normalize 25OHD status, then to continue with a supporting dose given monthly
(or even every two weeks, in view of the half-life of 25OHD of two weeks) based on body weight [4,5].
This approach seems to be efficient and at the same time safe and able to achieve a satisfying adherence
to the treatment of the elderly [4,5]. Due to its clinical practical relevance, as already indicated by the
algorithm used in the study from Wijnen et al., it is desirable to include the role of BMI in vitamin D
supplementation in further guidelines as well as vitamin D baseline levels [5].
3.1.2. Daily vs. Monthly Dose
To improve adherence of patients to treatment, a deferred regimen is proposed by many authors
as a valid alternative to daily treatment. However, there is growing evidence that infrequent high-dose
vitamin D supplements might be less effective or even harmful. Pekkarinen et al., in 2009, have shown
that supplementing vitamin D every four months is less efficient compared to the equivalent dose
in daily administration [50]; moreover, a double-blind, placebo-controlled trial of more than 2000
women aged 70 years or older showed a significant association between annual oral administration of
high-dose cholecalciferol and an increased risk of falls and fractures [36].
The effect of a loading dose in addition to daily vitamin D regimen in increasing vitamin D levels
was evaluated by Papaioannou et al., and the study showed no significant differences in 25OHD
values over three months of treatment, between the groups supplemented with or without a loading
dose [47]. This result might have been influenced by the difference of supplements used for loading
dose (vitamin D2) and daily administration (vitamin D3).
Meekiins et al., among 39 non-lactating women aged 18 years–40 years old, compared the different
pharmacokinetics of a 150,000 IU single dose vs. a 5.000 IU daily dose of cholecalciferol over 28 days,
and showed no difference in the cholecalciferol area under the curve between the two groups, although
the single dose group had a significantly greater mean of 25OHD [51].
Another study was set to evaluate the effect of daily and monthly dosing of D2 or D3 on circulating
25OHD; the frequency of dosing did not significantly impact 25OHD levels, but the compliance to
the treatment was higher in the monthly group. Additionally, the results showed that vitamin D3 is
significantly more effective than D2 in increasing serum 25OHD over 12 months [1].
The above-mentioned interesting study from Wijnen et al. in subjects with a mean age of 84 years,
compared the efficacy of an individualized cholecalciferol loading dose vs. a daily dose regimen of
cholecalciferol 800 IU; the loading dose was calculated according to the algorithm (40 × (25OHD target
level − 25OHD baseline level) × body weight), and administered in doses of 50,000 IU twice a week
until the total dose was reached [4]. The results showed that patients supplemented with a personalized
loading dose reached optimal vitamin D levels within five weeks, with a very large difference in
percentage of patients compared to the daily dose group. The administration of a loading dose based
on body weight and baseline 25OHD values seems to normalize vitamin D levels in a faster and much
more efficient way [4]. It also suggested that the supplementation doses recommended by some of the
current guidelines (i.e., Australia Osteoporosis, Institute of Medicine, Endocrine Society Clinical Practice
Guidelines) are possibly not effective in correcting vitamin D deficiency in the elderly population.
On the other hand, Bischoff-Ferrari et al. pointed out the controversial role of vitamin D
supplementation in the prevention of falls and fractures; the study involved 200 women, selected
on the basis of a prior fall, with a mean age of 78 years over one year, divided into three groups based
on different monthly vitamin D3 treatments: 24,000 IU/monthly (control group), 60,000 IU/monthly or
24,000 IU/monthly plus 300 mcg calcifediol. Although higher doses of supplements were more effective
in reaching reach levels of 30 ng/mL, there were no benefits to lower extremity function; moreover, in
the two high-dose groups the risk of falls was significantly increased [8]. This study showed a 5.5 times
greater risk of falling in patients reaching the highest quartile of 25OHD level (44.7 ng/mL–98.9 ng/mL)
compared with those reaching the lowest quartile (21.3 ng/mL–30.3 ng/mL), suggesting a U-shaped
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curve (rather than a J-shaped curve) correlation of the effect of vitamin D status on prevention of falls [8].
Further, Smith et al. supported the evidence of a U-shaped curve response to vitamin D3 dose and fall
rate and a potential difference between high and medium doses of vitamin D [52].
These results might support the conservative (although not completely effective) approach of
IOM recommendations of 800 IU/day of vitamin D3, and cautions against higher doses of vitamin D3,
even though they are required to obtain an optimal 25OHD target level [7].
While it is clear that 25OHD levels should be maintained up to a target level of 30 ng/mL, further
studies are required to identify a possible upper threshold for the safety of 25OHD levels.
The detrimental effects on efficacy and safeness of high and/or deferred doses of vitamin D
supplementation showed by the latest trials are not completely clear and are currently under investigation.
The negative outcome on bone health is probably also related to the fact that high doses of vitamin D
increase FGF-23 concentration, sclerostin and Dickkopf-1 (DKK-1). The sclerostin and DKK-1 increase
inhibits Wnt signaling, and might trigger an upregulation of 1,25-dihydroxyvitamin D3 24-hydroxylase,
resulting in increased metabolism and blood levels of 1,25-dihydroxyvitamin D3 [7,49,53].
In the studies we analyzed, no significant differences in hypercalcemia (rarely detected) or urinary
calcium levels were found between daily or deferred vitamin D supplements administration [1,47,50,51]
(Table 5).
Table 5. Synthetize findings from recent trials on vitamin D dosing regimen.
Study Design Efficacy (25-OHDLevel > 30 ng/mL) Safety
2011, Binkley et al. [1] 1600 IU daily vs. 50,000 IU monthly.64 adults over 1 year.
Similar efficacy.
19% of patients did not reach a
25-OHD level > 30 ng/mL.
No hypercalcemia detected.
Similar serum calcium levels.
2015, Wijnen et al. [4]
800 IU daily vs. Loading Dose
(40 × (25-OHD target − 25-OHD
baseline) × weight) + 50,000 or
25,000 IU monthly (LD).
30 adults over 26 weeks.
Daily group less efficient than
LD group (30% vs. 83%). Not applicable.
2016, Bischoff-Ferrari et al. [8]
24,000 IU vs. 60,000 IU vs. 24,000 IU +
300 ug calcifediol monthly.
200 adults with a prior fall over 1 year.
24,000 IU group less efficient
than 60,000 IU and 24,000 IU +
calcifediol (54.7% vs. 80.8%
and 83.3%).
Significant increasing in falls in
60,000 IU and 24,000 IU + calcifediol
groups compared to 24,000 IU
group (66.9–66.1% vs. 47.9%).
2011, Papaioannou et al. [47]
50,000 IU + 1000 IU daily vs. 100,000
IU + 1000 IU daily vs. placebo
+ 1000 IU daily.
65 adults over 90 days.
Similar efficacy.
25% of patients did not reach a
25-OHD level > 30 ng/mL.
Similar, all adverse events judged
unrelated to the study treatments.
2010, Pekkarinen et al. [50]
800 IU daily vs. 97,333 IU every
4 months (4M).
40 women over 1 year.
Daily group more efficient
than 4M (47% vs. 28%). Similar increase in urinary calcium.
2014, Meekiins et al. [51] 5000 IU daily vs. 150,000 IU once.39 women over 28 days.
Similar area under curve for
25-OHD level.
No relevant changes in serum
calcium or phosphorus.
4. Discussion
Timing and dosing regimen are crucial for vitamin D supplementation. Daily administration
is supposed to be the most physiological way to correct vitamin D deficiency, but a less frequent
administration is likely to improve patient compliance to the treatment, and help obtain a greater mean
vitamin D 25-hydroxylation [1,51].
In Italy in the first year of life, an intake of 400 IU/day from six to twelve months is
recommended [12], even though, as reported in Table 1, different international health organizations
give specific and sometimes slightly different recommendations due to different sun exposures and
study results. In children and adolescents from 1 to 18 years of age, the recommended daily intake
of Vitamin D is 600 IU/day, according to the American Academy of Pediatrics [30]. However, once
again, looking at Table 2, different international health organizations give different suggestions for the
1–18 age range. These recommendations come from studies where potentially conflicting factors were
considered and results were clearly different.
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Among the elderly too, as reported in Table 3, different international health organizations give
different recommendations for Vitamin D supplementation, introducing more confusion. To improve
adherence of patients to treatment, a deferred regimen is proposed by many authors as a valid
alternative to daily treatment, even though infrequent high-dose vitamin D supplement might be
less effective or even harmful. In Italy, in elderly subjects, the current recommendations suggest
normalizing 25OHD levels within few weeks with a loading dose based on baseline 25OHD
concentration, which is a simplification of the effective dose able to normalize vitamin D levels.
Interestingly, some authors suggest the use of a specific algorithm to calculate the loading dose,
combining vitamin D levels and weight [4,54]. This approach is interesting because it represents an
effort to define a more tailored treatment. From another point of view, the loading dose approach
has been criticized by other authors as a cause of increased risk of falls and fractures [7]. Moreover,
this negative result emerging from the study by Bischoff-Ferrari might be influenced by the selection
criteria (patients with a prior fall) and by the lack of a placebo group. From another point of view,
this conflicting result should be explained with the effect exerted by high doses of cholecalciferol that
induce an acute increase of FGF-23, and consequently of turnover [53]. Based on these observations,
the best approach seems to be a loading dose calculated using the abovementioned algorithm, followed
by a daily/monthly maintaining dose, chosen on the basis of the characteristics of the patient.
5. Conclusions
In summary, the best approach to correct a vitamin D deficiency is still debated and could be
specific for different age groups. To give clear and practical guidelines, it could be time to set up an
expert panel to identify the best dosage of vitamin D at different ages. Many other variables could be
included in the analysis to obtain the desirable dosage.
However, after a critical revision and analysis of all evidence, we could suggest, as key factors,
considering bone mass analysis in children and the role of weight or BMI in the elderly in order to
define “the Vitamin D picture”. It is also fundamental to ensure a correct acquisition of bone mass
which is known to reach its peak in adolescence, a process in which vitamin D is closely involved.
Finally, we can suggest the administration of a loading dose based on body weight and baseline
25OHD values to normalize vitamin D levels, while it is urgent to define the optimal regimen of
vitamin D supplementation for maintaining normal levels, having a clear picture of daily vs. monthly
administration, and low vs. high dosage.
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